letter – cannabis.co.nz

July 13, 20238, analysis, analytics, business, Business Analysis, candy, cannabis, cbd, claim, compliance, consumer, copycat, cure, Delta, delta 8, drug, Edibles & Processing, FDA, Federal, food, FTC, government, growing, Health, industry, law, legal, legalization, legalize, legislation, letter, license, marijuana, market, marketing, medical, medicine, product, regulation, regulations, regulatory, retail, safety, snack, state, test, thc, unsub, warning

FDA, FTC Issue Warnings to Delta 8 Copycat Cannabis Companies

Last week, the U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) sent out warning letters to six different […]

March 30, 2023analysis, analytics, announcement, Arnold & Porter, business, Business Analysis, cannabis, cbd, civil, claim, compliance, consumer, contaminate, contamination, delta 8, Edibles & Processing, FDA, Federal, government, industry, lab, laboratories, laboratory, labs, law, lawsuit, legal, legalization, legalize, legislation, letter, liability, liable, market, Operations, product, Product Development, Quality, recall, recreational, regulation, regulatory, retail, risk, safety, state, suit, test, Testing, thc, warning

Product Liability in the Cannabis Industry: Insights From 2022 & Looking Forward

In 2022, product liability lawsuits in the cannabis/cannabidiol (CBD) industry continued to focus on levels of THC and the psychoactive ingredient in […]

February 23, 2023analysis, analytics, attorney general, bill, business, Business Analysis, CA, california, cannabis, commerce, compliance, consumer, control, cultivation, department, dispensary, export, Federal, government, growing, import, industry, interstate, law, legal, legalization, legalize, legislation, legislator, letter, market, medical, medicine, of, product, Quality, recreational, regulation, regulatory, retail, safety, state, thc

California’s DCC Requests AG Opinion on Interstate Cannabis Commerce

On January 27 this year, Matthew Lee, General Counsel for the Department of Cannabis Control, sent a letter to Senior Assistant Attorney […]

May 5, 20228, analysis, analytics, business, cannabidiol, cannabis, cbd, claim, compliance, consumer, cure, Delta, delta-8 THC, delta-8-tetrahydrocannabinol, delta-9 tetrahydrocannabinol, delta-9-THC, Dispensaries & Retail, drug, Edibles & Processing, FD&C act, FDA, Federal, government, growing, illegal, industry, lab, label, laboratories, laboratory, law, legal, legalization, legalize, legislation, letter, license, marijuana, market, marketing, medical, medicine, misbranded, prevent, product, Quality, recreational, regulation, regulations, regulatory, retail, safety, state, test, Testing, thc, treat, unapproved, update, violate, violation, warning

FDA Issues First Warning Letters for Delta-8 THC

In an unprecedented move, the U.S. Food & Drug Administration (FDA) has issued warning letters today to companies selling products containing delta-8 […]

April 20, 2022action, analysis, analytics, approval, approved, business, Business Analysis, cannabidiol, cannabis, cbd, claim, compliance, Concentrates & Extracts, consumer, Coronavirus, COVID, COVID-19, cultivation, drug, Edibles & Processing, enforcement, extraction, farm bill, FD&C act, FDA, Federal, government, growing, Health, industry, lab, law, legal, legalization, legalize, legislation, letter, license, marijuana, market, medical, medicine, New, product, Product Development, Quality, regulation, regulations, regulatory, research, retail, safety, state, test, Testing, thc, threaten, U.S. Food and Drug Administration, unapproved, unsubstantiated, warning, wellness

FDA Warning Letters: Stop Claiming CBD Prevents COVID

Once again, the U.S. Food and Drug Administration (FDA) has issued a number of warning letters to companies selling hemp-derived cannabidiol (CBD) […]

March 26, 2021Act, active, advertised, advertising, analysis, analytics, and Cosmetic, approval, business, cannabidiol, cannabis, cbd, compliance, consumer, Dispensaries & Retail, drug, FDA, FDA food safety challenge, Federal, food, GMP, good manufacturing practice, government, growing, Husch Blackewell, inactive, industry, ingredient, law, legal, legalization, legalize, legislation, letter, license, marijuana, market, marketing, medical, medicine, NDA, New Drug Application, nonprescription, OTC, prescription, product, products, Quality, recreational, regulation, regulations, regulatory, retail, safety, state, test, Testing, thc, violation, warning

FDA Issues Warning Letters on Marketing and Sale of OTC CBD Products

The U.S. Food and Drug Administration (FDA) issued warning letters this month to two companies concerning the marketing and sale of over-the-counter (OTC) drug […]